Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |||
---|---|---|---|---|---|---|
Aktuell sind keine Nachrichten verfügbar, die den gewählten Kriterien entsprechen. |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
DAY ONE BIOPHARMACEUTICALS | 16,600 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2024 Financial Results and Corporate Progress | OJEMDA (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) First prescriptions received in the U.S. BRISBANE... ► Artikel lesen | |
CG ONCOLOGY | 35,100 | 0,00 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,940 | 0,00 % | Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? | ||
JANUX THERAPEUTICS | 62,19 | 0,00 % | Aktien New York: Dow erholt sich vor Start in die Berichtssaison | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben sich am Donnerstag im Handelsverlauf von ihrer anfänglichen Schwächephase erholt. Der Dow Jones Industrial notierte zuletzt 0,12 Prozent im Plus bei 38... ► Artikel lesen | |
EVOTEC | 9,555 | -0,52 % | EQS-News: Evotec SE: Bayer und Evotec vereinbaren Forschungskollaboration in der Präzisionskardiologie | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Bayer und Evotec vereinbaren Forschungskollaboration in der Präzisionskardiologie
30.04.2024 / 08:30 CET/CEST
Für den... ► Artikel lesen | |
IMMUNOVANT | 29,670 | 0,00 % | Pre-market Movers: Kaival Brands, Lufax Holding, Tourmaline Bio, Laser Photonics Corporation, Immunovant | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green Kaival Brands Innovations Group... ► Artikel lesen | |
KEROS THERAPEUTICS | 60,26 | 0,00 % | Keros Therapeutics files automatic mixed shelf | ||
BEAM THERAPEUTICS | 22,780 | 0,00 % | Beam Therapeutics Inc. - 10-Q, Quarterly Report | ||
STRUCTURE THERAPEUTICS | 39,740 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights | Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in obesity... ► Artikel lesen | |
QIAGEN | 39,780 | +0,39 % | Zahlenflut im DAX: Adidas, Covestro, Mercedes-Benz, MTU, Qiagen, Volkswagen und Vonovia im ... | Am Montag hat der DAX im Tagesverlauf kontinuierlich an Wert verloren und am Ende mit 42 Pünktchen im Minus geschlossen. Relativ unverändert geht es in den Handelstag am Dienstag, wobei die Marktteilnehmer... ► Artikel lesen | |
SIGA TECHNOLOGIES | 10,390 | 0,00 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
ARVINAS | 32,260 | 0,00 % | Arvinas Inc.: Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update | - Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study... ► Artikel lesen | |
ARCELLX | 52,67 | 0,00 % | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 20,600 | 0,00 % | Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
NUVALENT | 69,25 | 0,00 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen |